theMednetRegister

Medical Oncology

ASTRO 2025   

ASTRO 2025 Annual Meeting

Questions discussed in this category

How will you select patients with brain metastases for TTFields?
The METIS study included only NSCLC patients and found a greater impact for patients previously treated with ICI. How does this impact your patient se...
2 Answers available
When do you consider using protons for breast cancer?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
4 Answers available
Would patients receiving targeted therapies be eligible for TTFields for brain metastases?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
3 Answers available
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
2 Answers available
In a patient undergoing neoadjuvant 177Lu-PNT2002 + MDT for oligorecurrent prostate cancer as per the LUNAR trial, what are the implications for other escalated systemic therapies with ARPIs/chemotherapy, which may otherwise be used concurrent with ADT in this population?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
1 Answer available
Does the choice of radiation modality (3D, IMRT/VMAT, protons) impact the effectiveness of the reduced dose of 20 Gy in DLBCL?
Would you prefer certain modalities if using the lower dose?   This question is part of our collaboration with ASTRO 2025 to highlight impactfu...
1 Answer available
What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?
Should the reduced dose be adopted for all, or would you reserve this approach for specific patient subgroups?   This question is part of our c...
1 Answer available


Papers discussed in this category

International journal of radiation oncology, biology, physics, 2017-04-01
Utility of Deep Inspiration Breath Hold for Left-Sided Breast Radiation Therapy in Preventing Early Cardiac Perfusion Defects: A Prospective Study.
Brachytherapy, 2018
The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation.
The New England journal of medicine, 2013-03-14
Risk of ischemic heart disease in women after radiotherapy for breast cancer.
Breast Cancer Res. Treat., 2020 Apr 03
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
International journal of radiation oncology, biology, physics, 2025 Feb 22
Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma.
The Lancet. Oncology, 2025 Mar
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.
The Lancet. Oncology, 2025 Mar
Destroy or delay: hormonal therapy in oligometastatic prostate cancer.
The Lancet. Oncology, 2023 Sep
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

Related Topics in Medical Oncology

Copyright © 2025 theMednet
All Rights Reserved.